Vascular Changes in Hepatocellular Carcinoma
- 16 May 2008
- journal article
- review article
- Published by Wiley in The Anatomical Record
- Vol. 291 (6) , 721-734
- https://doi.org/10.1002/ar.20668
Abstract
Hepatocellular carcinoma (HCC) is one of the most vascular solid tumors, in which angiogenesis plays an important role. The status of angiogenesis in HCC correlates with the disease progression and prognosis, and thus provides a potential therapeutic target. This review summarizes the vascular changes and molecular and cellular basis of angiogenesis in HCC. Development of HCC is characterized by arterialization of its blood supply and sinusoidal capillarization. Vascular endothelial growth factor (VEGF) is a potent angiogenic factor that plays a critical role in mediating angiogenesis in HCC. The VEGF can function on various types of cells, such as endothelial cells, hepatic stellate cells, endothelial progenitor cells and hemangiocytes, to induce vascular changes in HCC. Therefore, blockade of VEGF-mediated pathways, either by anti-VEGF neutralizing antibody or tyrosine kinase inhibitors that target VEGF receptors, suppresses carcinogenesis and angiogenesis in HCC. In addition to VEGF, several other angiogenic factors in HCC have recently been identified. These factors can also regulate angiogenic processes through interaction with VEGF or VEGF-independent pathways. Despite the fact that treatment of HCC remains a tough task due to lack of effective systemic therapy, antiangiogenic therapy has already entered clinical trials in HCC patients and sheds light on a promising novel treatment for this disease.Keywords
This publication has 140 references indexed in Scilit:
- Flt‐1, but not Flk‐1 mediates hyperpermeability through activation of the PI3‐K/Akt pathwayJournal of Cellular Physiology, 2007
- Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4British Journal of Cancer, 2006
- Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytesNature Medicine, 2006
- Thalidomide in the treatment of patients with hepatocellular carcinomaCancer, 2005
- Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectivesZeitschrift für Krebsforschung und Klinische Onkologie, 2004
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002
- The growth inhibition of hepatoma by gene transfer of antisense vascular endothelial growth factorThe Journal of Gene Medicine, 2000
- Hepatic stellate cell activation in dysplastic nodules: evidence for an alternate hypothesis concerning human hepatocarcinogenesisLiver International, 1997
- Inhibitory effect of the angiogenesis inhibitor TNP-470 on tumor growth and metastasis in nude mice bearing human hepatocellular carcinomaZeitschrift für Krebsforschung und Klinische Onkologie, 1997
- Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growthNature, 1987